GA-UNIBLOC-PUMP
8.9.2021 13:17:10 CEST | Business Wire | Press release
Unibloc Pump , a 37-year leader in the manufacture of positive displacement pumps, strainers, valves, bubble traps, and other solutions for sanitary flow control applications, today announced the acquisition of Flotronic Pumps , a UK-based manufacturer of specialized, air operated double diaphragm (AODD) pumps, and associated accessories. Founded in 1990, Flotronic Pumps has a global reputation as the inventor of the ‘One Nut’ AODD pump. Flotronic Pumps’ pioneering single bolt design significantly reduces process downtime by simplifying pump assembly / disassembly, providing savings in maintenance costs along with best-in-class air pump performance. Flotronic Pumps serves more than 1,000 global companies operating manufacturing facilities of iconic brands in food and beverage, consumer product goods, cosmetics, pharmaceuticals, and other critical process manufacturing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005041/en/
Terms of the agreement were not disclosed. Flotronic Pumps will be solely owned by US-based Unibloc Pump while retaining its name, Flotronic Pumps Ltd. Joining the leadership team at Flotronic Pumps as chief executive officer will be Chris Stevens, the CEO of Unibloc Pump. Stevens will provide commercial leadership with strengths in business-to-business marketing, channel management, sales, and overall business management.
“This acquisition is a perfect hand-in-glove fit for Unibloc Pump.” Stevens said. “Unibloc Pump and Flotronic Pumps are ready to drive accelerated growth by offering customers products and solutions fueled by our passions for innovation, safety, and simplicity in maintenance to avoid downtime and increase efficiencies,” Stevens added.
Through the leadership of owner Stuart Whitehouse and the deep expertise of Director of Sales Leighton Jones, Flotronic Pumps has witnessed significant growth in Europe, as well as North America. “What we really like most of all about joining the Unibloc Pump family is that we share many of the same cultural values of simplicity in product design, quality in products, unabashed customer-focus, deep industry expertise, and a penchant for strong innovation,” said Jones. “These qualities will ensure that Unibloc Pump and Flotronic Pumps will be successful moving forward by flourishing through common bonds,” added Jones.
“Important to this acquisition is that both companies share complementary market footprints,” commented Whitehouse. “The combination will enable Unibloc Pump to grow its UK and European business, while also giving Flotronic Pumps an unmatched North American foothold. That should pay off in greater market coverage and increased overall value delivered to the customer,” Whitehouse added.
Unibloc Pump seeks to expand its vision to build a global sanitary flow control platform that delivers operational excellence, while targeting highly regulated hygienic end market applications, such as food and beverage, meat and poultry, and pharmaceutical processing. Unibloc Pump’s investment in Flotronic Pumps will provide resources to allow both companies to continue to grow and strengthen their global businesses.
The acquisition will allow Flotronic Pumps to leverage Unibloc Pump’s operational, manufacturing, sales, and distribution capabilities in North America out of its Kennesaw, GA facility. Likewise, Unibloc Pump will utilize Flotronic Pumps’ operations, manufacturing, sales, and distribution footprint in the United Kingdom and other European markets to further complement Unibloc’s existing European operation, Unibloc-R&H GmbH , based in Beckum, Germany.
Unibloc Pump is a portfolio company of May River Capital, a Chicago-based private equity firm devoted to helping high-caliber, lower middle-market industrial businesses grow and thrive. May River Capital takes pride in its unique approach and track record of building businesses through long-term partnership and collaboration. Its leadership team has broad experience helping promising companies become successful mid-size industrial businesses.
ABOUT UNIBLOC PUMP
Since 1984, Unibloc Pump has provided manufacturers in the food and beverage, pharmaceutical, bakery and confection, meat and poultry, brewery, and transportation industries with precision-engineered sanitary pumps, strainers, valves, bubble traps, and other accessory products to tackle the toughest sanitary jobs. Unibloc Pump is the premier designer of efficient, easy-to-clean pumps that help customers fight downtime, achieve a lower cost of operation, and meet deadlines with confidence. For more information, please visit www.uniblocpump.com .
ABOUT FLOTRONIC PUMPS
Based in West Sussex, United Kingdom and founded in 1990, Flotronic Pumps is a manufacturer of specialized AODD pumps and associated accessories. Flotronic’s products take performance far beyond traditional style AODD pump technology with a distinctive single bolt design that allows for in-line assembly / disassembly to be accomplished quickly and efficiently, significantly reducing process downtime, while providing best-in-class performance. For more information, please visit www.flotronicpumps.com .
ABOUT MAY RIVER CAPITAL
May River Capital is a Chicago-based private equity firm focused on investing in lower middle-market, industrial growth companies. May River Capital invests in high-quality industrial growth businesses, including precision manufacturing, engineered products and instrumentation, specialized industrial services, and value-added industrial distribution services. For more information, please visit www.mayrivercapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
